Author:
Okamoto Aikou,Glasspool Rosalind M.,Mabuchi Seiji,Matsumura Noriomi,Nomura Hiroyuki,Itamochi Hiroaki,Takano Masashi,Takano Tadao,Susumu Nobuyuki,Aoki Daisuke,Konishi Ikuo,Covens Alan,Ledermann Jonathan,Mezzazanica Delia,Steer Christopher,Millan David,McNeish Iain A.,Pfisterer Jacobus,Kang Sokbom,Gladieff Laurence,Bryce Jane,Oza Amit
Abstract
AbstractClear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.
Subject
Obstetrics and Gynecology,Oncology
Cited by
110 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献